Reference
1. Park SH, Chi HS, Cho YU, et al. Effects of c-KIT mutations on
expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)positive
acute myeloid leukemia patients. Leuk Res. 2013;37: 784-789.
2. Muller AM, Duque J, Shizuru JA, Lubbert M. Complementing mutations in
core binding factor leukemias: from mouse models to clinical
applications. Oncogene. 2008;27:5759-5773.
3. Krauth MT, Eder C, Alpermann T, et al. High number of additional
genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1RUNX1T1:
Frequency and impact on clinical outcome. Leukemia. 2014;28:1449-1458.
4. Yu G, Yin C, Wu F, et al. Gene mutation profile and risk
stratification in AML1ETO-positive acute myeloid leukemia based on
nextgeneration sequencing. Oncol Rep. 2019; 42: 2333-2344.
Duployez N, Marceau‑Renaut A, et al. Comprehensive mutational
profiling of core binding factor acute myeloid leukemia. Blood.
2016;127: 2451‑2459.
6. Qin YZ, Zhu HH, Jiang Q, et al. Prevalence and prognostic
significance of c‑KIT mutations in core binding factor acute myeloid
leukemia: A comprehensive large‑scale study from a single Chinese
center. Leuk Res. 2014;38:1435‑1440.
7. Yu G, Yin C, Jiang L, et al. Amyloid precursor protein has clinical
and prognostic significance in AML1ETOpositive acute myeloid leukemia.
Oncol Lett. 2018;15: 917-925.
8. Klein K, Kaspers G, Harrison CJ, et al. Clinical Impact of
Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and
Treatment Elements in Pediatric t(8;21)-AML: Results From an
International Retrospective Study by the International
Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2015;33:4247-4258.
9. Abdel RH, Farrag SA, El-Attar IA. AML1/ETO Fusion Gene in de novo
Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic
Implications. J Egypt Natl Canc Inst. 2007;19:39-47.
10. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the
world health organization classification of myeloid neoplasms and acute
leukemia. Blood. 2016;127: 2391-2405.
Støve HK, Sandahl JD, Abrahamsson J, et al. Extramedullary leukemia in
children with acute myeloid leukemia: A population‐based cohort study
from the Nordic Society of Pediatric Hematology and Oncology (NOPHO).
Pediatr Blood Cancer. 2017;64(12). doi: 10.1002/pbc.26520.
12. Yu G, Yin C, Jiang L, et al. Amyloid precursor protein cooperates
with C-KIT mutation/overexpression to regulate cell apoptosis in
AML1-ETO-positive leukemia via PI3K/AKT signaling pathway. Oncol Rep.
2016;36:1626-1632.
13. Yin JA, O’Brien MA, Hills RK, et al. Minimal residual disease
monitoring by quantitative RT-PCR in core binding factor AML allows risk
stratification and predicts relapse: results of the United Kingdom MRC
AML-15 trial. Blood. 2012;120:2826-2835.
14. Jiang L, Yu G, Meng W, et al. Overexpression of amyloid precursor
protein in acute myeloid leukemia enhances extramedullary infiltration
by MMP-2. Tumour Biol. 2013; 34: 629-636.
15. Jiang L, Meng W, Yu GP, et al. MicroRNA144 targets APP to regulate
AML1/ETO+ leukemia cell migration via the pERK/cMyc/MMP2 pathway. Oncol
lett. 2019; 18: 2034-2042.
16. Zhang MY, Zheng CY, Zou MM, et al. Lamotrigine attenuates deficits
in synaptic plasticity and accumulation of amyloid plaques in APP/PS1
transgenic mice. Neurobiol Aging. 2014;35:2713-2725.
17. Hansel DE, Rahman A, Wehner S, et al. Increased expression and
processing of the Alzheimer amyloid precursor protein in pancreatic
cancer may influence cellular proliferation. Cancer Res.
2003;63:7032-7037.
18. Ko SY, Lin SC, Chang KW, et al. Increased expression of amyloid
precursor protein in oral squamous cell carcinoma. Int J Cancer.
2004;111:727-732.
19. Takayama K, Tsutsumi S, Suzuki T, et al. Amyloid precursor protein
is a primary androgen target gene that promotes prostate cancer growth.
Cancer Res. 2009;69:137-142.
20. Baldus CD, Liyanarachchi S, Mrózek K, et al. Acute myeloid leukemia
with complex karyotypes and abnormal chromosome 21: Amplification
discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci
USA. 2004;101:3915-3920.
21. Wang W, Meng FY, Huang ZF, et al. Expression and role of amyloid
precrusor protein gene in acute myeloid leukemia. Chin J Hematol.
2010;31:309-14 (In Chinese).
22. Rubnitz JE, Raimondi SC, Hallbert AR, et al. Characteristics and
outcome of t(8;21)-positive childhood acute myeloid leukemia: A single
institution’s experience. Leukemia. 2002;16:2072-2077.
23. Lan TY, Lin DT, Tien HF, et al. Prognostic factors of treatment
outcomes in patients with granulocytic sarcoma. Acta Haematol.
2009;122:238-246.
24. Byrd JC,Weiss RB, Arthur DC, at al.Extramedullary leukemia
adversely affects hematologic complele remission rate and overall
survival in patients with t(8;2 1)(q22;q22):results from Cancer and
Leakemia Group B8461.J Clin Oncol. 1997; 15: 466-475.
25. Lai YY, Qiu JY, Jiang B, et al. Characteristics and prognostic
factors of acute myeloid leukemia with t( 8; 21) ( q22; q22). Journal of
Experimental Hematology. 2005; 13( 5) : 733- 740.
26. Felice MS, Zubizarreta PA, Alfaro EM, et al. Good outcome of
children with acute myeloid leukemia and t(8;21)(q22;q22), even when
associated with granulocytic sarcoma: a report from a single institution
in Argentina. Cancer. 2000; 88(8):1939–1944.
27. Kobayashi R, Tawa A, Hanada R, et al. Extramedullary infiltration at
diagnosis and prognosis in children with acute myelogenous leukemia.
Pediatr Blood Cancer. 2007;48(4):393-398.
28. Voigt AP, Brodersen LE, Alonzo TA, et al. Phenotype in combination
with genotype improves outcome prediction in acute myeloid leukemia: a
report from Children’s Oncology Group protocol AAML0531. Haematologica.
2017;102:2058-2068.
29. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic
significance of KIT mutations in pediatric patients with core binding
factor AML enrolled on serial pediatric cooperative trials for de novo
AML. Blood. 2010;115:2372-2379.
30. Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of
receptor tyrosine kinases and Ras genes in childhood core-binding factor
acute myeloid leukemia and a comparative analysis on paried diagnosis
and relapse samples. Leukemia. 2008;22:303-307.
31. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute
myeloid leukemia. N Engl J Med. 2011;364:1027-1036.
32. Acute myeloid leukemia, Version 3.2020, 12/23/19 © 2019 National
Comprehensive Cancer Network® (NCCN®). http://guide.medlive.cn.
33. Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese
Medical Association. Chinese guildlines for diagnosis and treatment of
adult acute lyeloid leukemia (not APL) (2017). Chin J Hematol.
2017;38:177-184.